Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Amgen

Revenues flat in the quarter as declines for flagship products offsets sales growth for newer products

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen
1Q Revenues: $5.6 billion (flat)
1Q Earnings: $2.0 billion (-14%)
Comments: Enbrel sales increased 4% to $1.2 billion. Prolia sales increased 20% to $592 million. XGEVA sales increased 6% to $471 million. KYPROLIS sales increased 10% to $245 million. Repatha sales increased 15% to $141 million. Parsabiv sales increased 207% to $126 million driven by higher unit demand, offset partially by net selling price. Vectibix sales increased 1% to $170 million. Nplate sales increased 6% to $189 million. BLINCYTO sales increased 41% to $69 million. Neulasta sales were down 12% driven primarily by lower net selling price and, to a lesser extent, changes in inventory. NEUPOGEN sales were down 29% primarily due to the impact of competition on unit demand and net selling price. EPOGEN sales decreased 10% driven primarily by lower net selling price. Aranesp sales decreased 9% due to competition. Sensipar/Mimpara sales were down 57% due to competition.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters